The global mRNA vaccine market is undergoing a significant transition phase following the unprecedented surge during the COVID-19 pandemic. Valued at US$ 21.7 billion in 2023, the market is projected to decline to over US$ 9.6 billion by 2034, registering a negative CAGR of -4.3% during the forecast period. While this contraction reflects the normalization of pandemic-driven demand, the...